While this points out the interest of the β-catenin–BCL9/9L complex as a potential therapeutic target for CRC, it also raises the need to validate, in the end, the direct implication of BCL9/9L in the generation of the BCL9/9L-KO signature in human cells, considering the fact that BCL9/9L have been found to be expressed in all tumor samples. The gene discussed is BCL9; the disease is colorectal carcinoma.